FDA approves Neurocrine Biosciences’ Ingrezza for tardive dyskinesia
Neurocrine Biosciences has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its medication, Ingrezza (valbenazine) capsules, for the treatment of ... Read More
FDA approves Genentech’s Ocrevus for multiple sclerosis treatment
In a landmark decision, the US Food and Drug Administration (FDA) has granted approval to Genentech, a subsidiary of the Roche Group, for its multiple ... Read More
Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the ... Read More
Lilly’s breast cancer drug abemaciclib shows promising results in phase 3 trial
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination ... Read More
Bayer and Janssen’s Xarelto shows promising results in reducing blood clot recurrence
Bayer AG and Janssen Pharmaceuticals, two giants in the pharmaceutical industry, have announced significant findings from their EINSTEIN CHOICE clinical trial, showcasing the effectiveness of ... Read More
AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for ... Read More
Amgen’s Repatha proves effective in major cardiovascular outcomes study
Amgen Inc. has achieved a significant milestone with its cholesterol-lowering injection, Repatha (evolocumab), demonstrating a 20% reduction in heart attack and stroke risks among patients ... Read More
TiGenix reports success for AlloCSC-01 in Phase I/II heart failure study
TiGenix, a Belgium-based biopharmaceutical company, has announced promising results from its Phase I/II study assessing the safety and efficacy of AlloCSC-01, its innovative stem cell ... Read More
FDA clears Servier and Pfizer for clinical development of UCART19 for acute lymphoblastic leukemia
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with the clinical development ... Read More
EC approves Actelion’s Ledaga for treatment of cutaneous T-cell lymphoma
The European Commission (EC) has granted marketing authorization to Actelion Pharmaceuticals for its innovative Ledaga Chlormethine Gel 160 micrograms/g, designed for the treatment of cutaneous ... Read More